Literature DB >> 2936982

Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting.

O Isacson, P Brundin, F H Gage, A Björklund.   

Abstract

The acute and long-term changes following large neostriatal ibotenic acid lesions and intrastriatal striatal neuronal grafting have been studied neurochemically by determinations of the gamma-aminobutyrate (GABA) and acetylcholine-synthetic enzymes, glutamate decarboxylase and choline acetyltransferase, and of dopamine and its primary acidic metabolite, 3,4-dihydroxyphenylacetic acid. The neurochemical data have been matched with estimates of tissue volume changes and striatal graft development through tissue weight and protein content analysis and histological volumetric measurements. Injections of 20 micrograms ibotenic acid, deposited over four injection sites in the head of the caudate-putamen, had by one week caused a 70-85% reduction in glutamate decarboxylase and choline acetyltransferase activity. With time there was a progressive recovery of the specific enzyme activities in the lesioned areas (expressed per microgram protein or per mg wet weight) to 40-60% of control levels as determined at 20 weeks post-lesion in the caudate-putamen. This increase was, however, largely if not exclusively due to the long-term shrinkage of the lesioned caudate-putamen, amounting to 50-70% at 20 weeks. Thus, the total glutamate decarboxylase and choline acetyltransferase activity levels in the lesioned caudate-putamen remained virtually unchanged (between 15 and 25% of control) over the 20 week experimental period. Glutamate decarboxylase activity was also markedly reduced (35-70%) in the two primary striatal projection areas, globus pallidus and substantia nigra, and there were no signs of recovery over time. Striatal dopamine levels, which were acutely unaffected by the lesion, showed a slow decline so that the total dopamine content in the area was reduced by about 80% at 20 weeks. Suspended striatal neurons obtained from the striatal primordia of 14-15-day-old rat fetuses, injected into the previously lesioned caudate-putamen, survived and established a new striatum-like structure at the site of the ibotenic acid lesion. The final volume of the graft tissue reached up to about 10 mm3 in volume and reduced striatal atrophy on average from about 50 to 70% of normal control in the rats with lesions to about 30-40% in the animals with grafts. In the rats with grafts, there was a significant recovery of glutamate decarboxylase and choline acetyltransferase activities not only in the lesioned caudate-putamen, containing the graft (from 20-25% to 40-50%, when expressed as total enzyme activity levels), but also the glutamate decarboxylase activity in the globus pallidus, a structure located at a distance from the graft.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2936982     DOI: 10.1016/0306-4522(85)90095-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  22 in total

1.  Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease.

Authors:  P Hantraye; D Riche; M Maziere; O Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.

Authors:  Jodi L McBride; Shilpa Ramaswamy; Mehdi Gasmi; Raymond T Bartus; Christopher D Herzog; Eugene P Brandon; Lili Zhou; Mark R Pitzer; Elizabeth M Berry-Kravis; Jeffrey H Kordower
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-02       Impact factor: 11.205

3.  Afferent and efferent connections of striatal grafts implanted into the ibotenic acid lesioned neostriatum in adult rats.

Authors:  M Pritzel; O Isacson; P Brundin; L Wiklund; A Björklund
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

4.  Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology.

Authors:  T B Freeman; F Cicchetti; R A Hauser; T W Deacon; X J Li; S M Hersch; G M Nauert; P R Sanberg; J H Kordower; S Saporta; O Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

5.  Progressive reparative gliosis in aged hosts and interferences with neural grafts in an animal model of Huntington's disease.

Authors:  Yvona Mazurová; Ivan Látr; Jan Osterreicher; Ivana Guncová
Journal:  Cell Mol Neurobiol       Date:  2006-06-14       Impact factor: 5.046

6.  Embryonic striatal grafts reverse the disinhibitory effects of ibotenic acid lesions of the ventral striatum.

Authors:  P J Reading; S B Dunnett
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

7.  Neural grafting to ischemic lesions of the adult rat hippocampus.

Authors:  N Tønder; T Sørensen; J Zimmer; M B Jørgensen; F F Johansen; N H Diemer
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

8.  Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat.

Authors:  D M Frim; T A Uhler; W R Galpern; M F Beal; X O Breakefield; O Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

9.  Therapeutic Strategies in Huntington's Disease.

Authors:  Ichiro Kanazawa
Journal:  J Clin Neurol       Date:  2006-12-20       Impact factor: 3.077

10.  Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.

Authors:  Rona K Graham; Mahmoud A Pouladi; Prasad Joshi; Ge Lu; Yu Deng; Nan-Ping Wu; Bryan E Figueroa; Martina Metzler; Véronique M André; Elizabeth J Slow; Lynn Raymond; Robert Friedlander; Michael S Levine; Blair R Leavitt; Michael R Hayden
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.